Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 147 results found. Search for [ bharat biotech covaxin efficacy ]

Results 1 to 21 of 147
PTI
April 28, 2021
Developed by Bharat Biotech in partnership with National Institute of Virology and the Indian Council of Medical Research, Covaxin was approved for emergency use on January 3


BusinessToday.In
April 25, 2021
The Hyderabad-based vaccine manufacturer has submitted updated accelerated and real-time stability data of Coaxin along with the justification for the extension of shelf life


BusinessToday.In
April 24, 2021
At these rates, Covaxin will be twice as costly as Covishield, which will be sold to state governments at Rs 400 per dose and to private hospitals at Rs 600 per dose in Phase 3 of vacccination drive


BusinessToday.In
New Delhi, April 22, 2021
Bharat Biotech's COVID-19 vaccine has shown an overall interim clinical efficacy of 78 per cent and 100 per cent efficacy against severe COVID-19 disease; Putting tremendous pressure on the nation's medical infrastructure, the latest surge in COVID-19 cases has driven up the demand for medical oxygen, a critical commodity in treating the respiratory ailment; At the current pace of vaccination against coronavirus, India would need another 8 years and 9 months to inoculate 70 per cent of its entire population, a threshold required to achieve herd immunity. Watch this and more news on News Blast. Read | COVID-19: Tips from psychologists to cope in these uncertain timesAlso Read | AUMs of Indian Mutual Fund industry decreases 0.5% m-o-m


Rashi Bisaria
New Delhi, April 22, 2021
New COVID-19 mutant in Bengal, escapes antibodies' immunity Scientists have found a new lineage of the SARS-CoV-2 virus named 'B.1.618' in India, which is predominantly circulating in West Bengal. This is the second lineage to be identified from the country. The infection through this variant makes plasma therapy as redundant as an investigational treatment. 600% jump in oxygen demand from hospitals Putting tremendous pressure on the nation's medical infrastructure, the latest surge in ...


Joe C Mathew
April 21, 2021
\"Efficacy against SARS-Cov-2 has been established. COVAXIN has demonstrated an excellent safety record in human clinical trials and in usage under emergency use,\" said Dr Krishna Ella, MD & Chairman, Bharat Biotech


BusinessToday.In
April 21, 2021
The ICMR has said that the vaccine developed by Bharat Biotech is effective against the UK and Brazil variants of SARS-CoV-2 and the double mutant strain of the virus


BusinessToday.In
April 13, 2021
Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev added that Sputnik V's production at a larger scale will start by July 2021 with plans to produce 500 million doses


BusinessToday.In
April 12, 2021
Of around 20 coronavirus vaccines in several clinical and pre-clinical stages, Russia's Sputnik V may get SEC's nod first


BusinessToday.In
April 11, 2021
Russian Direct Investment Fund (RDIF) has tied up with a host of Indian pharma companies such as Dr Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the production of Sputnik V


BusinessToday.In
April 9, 2021
The move by the national committee on adverse effects following immunisation (AEFI) has come after the European's regulator said it found rare cases of blood clots among some adult recipients who were given AstraZeneca-Oxford university's vaccine shots


BusinessToday.In
April 6, 2021
Adar says Covishield has found an excellent response below the age of 50 with one dose. About 70 per cent of people are fully protected with one dose, but the second dose is necessary for long-term immunity protection, he adds


BusinessToday.In
April 2, 2021
A subject expert committee (SEC) of the DCGI has allowed Bharat Biotech to give the third dose of Covaxin to a few volunteers six months after the second dose


BusinessToday.In
March 27, 2021
SII has signed an agreement with Novavax to manufacture a vaccine with the name 'Covovax' in India. Novavax has announced final efficacy of 96.4 per cent against original COVID-19 virus. Novavax with Serum will provide 1.1 billion cumulative doses for COVAX Facility


BusinessToday.In
March 9, 2021
The most common adverse event in the phase 2 trial was pain at the injection site, followed by headache, fatigue, and fever.


PTI
March 4, 2021
The high court also asked the Centre to explain in affidavit the rationale behind keeping strict control over class of persons who can be vaccinated against COVID-19


BusinessToday.In
March 4, 2021
Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus


Reuters
March 4, 2021
Government data shows that only 10% of about 12.6 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said


Rashi Bisaria
New Delhi, March 4, 2021
Digital media norms to be administered by Centre, not states The Information and Broadcasting (I&B) Ministry on Wednesday issued memorandum to states and union territories saying that the new rules for digital news publishers and over-the-top (OTT) platforms are to be administered by the Centre, not the states. The government had notified the Information Technology (Intermediary Guidelines and Digital Media Ethics Codes) Rules, 2021 on February 25. Defence equipment sales to India sho...


BusinessToday.In
March 4, 2021
Very early this morning, our first half a million doses of the AstraZeneca-Oxford vaccine from the Serum Institute arrived in Canada, said Prime Minister Justin Trudeau


PAGES 1 OF 8  12345